Viking The_老虎社区_美港股上老虎

Viking Therapeutics(VKTX.US)暴涨逾100%，最高触及77.17美元，此前该公司宣布其减肥药VK2735的二期试验取得积极结果。减肥药巨头诺和诺德(NVO.US)、礼来(LLY.US)跌约1.7%。据悉，VK2735是一种GLP-1受体激动剂，Viking正在开发一种可注射和口服的减肥药，用于治疗肥胖症和糖尿病。该试验满足了所有主要和次要终点，显示与安慰剂相比，在所有剂量下体重都具有统计学上的显著降低。接受每周剂量药物治疗的患者在13周后体重比基线下降了14.7%。

[2月27日] [0x感谢您的关注，您的关注是我分享的动力!]
$VikingTherapeutics,Inc.(VKTX)$ $Facebook(META)$ $特斯拉(TSLA)$

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":278669977886768,"tweetId":"278669977886768","gmtCreate":1709044560599,"gmtModify":1709194624863,"author":{"id":3444295152483709,"authorId":3444295152483709,"authorIdStr":"3444295152483709","name":"0x禅一","avatar":"https://static.tigerbbs.com/e095a6de5fc7261cf5533cea3887df0a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.01","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":128,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>Viking Therapeutics(VKTX.US)暴涨逾100%，最高触及77.17美元，此前该公司宣布其减肥药VK2735的二期试验取得积极结果。减肥药巨头诺和诺德(NVO.US)、礼来(LLY.US)跌约1.7%。据悉，VK2735是一种GLP-1受体激动剂，Viking正在开发一种可注射和口服的减肥药，用于治疗肥胖症和糖尿病。该试验满足了所有主要和次要终点，显示与安慰剂相比，在所有剂量下体重都具有统计学上的显著降低。接受每周剂量药物治疗的患者在13周后体重比基线下降了14.7%。\n \n [2月27日] [0x感谢您的关注，您的关注是我分享的动力!]&nbsp; \n $VikingTherapeutics,Inc.(VKTX)$ $Facebook(META)$ $特斯拉(TSLA)$</body></html>","htmlText":"<html><head></head><body>Viking Therapeutics(VKTX.US)暴涨逾100%，最高触及77.17美元，此前该公司宣布其减肥药VK2735的二期试验取得积极结果。减肥药巨头诺和诺德(NVO.US)、礼来(LLY.US)跌约1.7%。据悉，VK2735是一种GLP-1受体激动剂，Viking正在开发一种可注射和口服的减肥药，用于治疗肥胖症和糖尿病。该试验满足了所有主要和次要终点，显示与安慰剂相比，在所有剂量下体重都具有统计学上的显著降低。接受每周剂量药物治疗的患者在13周后体重比基线下降了14.7%。\n \n [2月27日] [0x感谢您的关注，您的关注是我分享的动力!]&nbsp; \n $VikingTherapeutics,Inc.(VKTX)$ $Facebook(META)$ $特斯拉(TSLA)$</body></html>","text":"Viking Therapeutics(VKTX.US)暴涨逾100%，最高触及77.17美元，此前该公司宣布其减肥药VK2735的二期试验取得积极结果。减肥药巨头诺和诺德(NVO.US)、礼来(LLY.US)跌约1.7%。据悉，VK2735是一种GLP-1受体激动剂，Viking正在开发一种可注射和口服的减肥药，用于治疗肥胖症和糖尿病。该试验满足了所有主要和次要终点，显示与安慰剂相比，在所有剂量下体重都具有统计学上的显著降低。接受每周剂量药物治疗的患者在13周后体重比基线下降了14.7%。 [2月27日] [0x感谢您的关注，您的关注是我分享的动力!] $VikingTherapeutics,Inc.(VKTX)$ $Facebook(META)$ $特斯拉(TSLA)$","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":2,"favoriteSize":0,"link":"https://laohu8.com/post/278669977886768","repostId":0,"isVote":1,"tweetType":1,"viewCount":1924,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["VKTX"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":505,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/278669977886768"}